Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Sanofi

Sanofi ( ($FR:SAN) ) has issued an announcement. Sanofi has reported updated figures for its share capital structure as of July 31, 2026, disclosin...

Sanofi Updates Share Capital and Voting Rights as of July 31, 2026

In a report released today, Fernando Garcia from RBC Capital maintained a Buy rating on Naturgy Energy Group, S.A., with a price target of €32.00. ...

RBC Capital Sticks to Its Buy Rating for Naturgy Energy Group, S.A. (0NPV)

Sanofi ( ($FR:SAN) ) just unveiled an announcement. Sanofi has secured European Commission approval to extend the use of its MenQuadfi meningococca...

Sanofi Wins EU Nod to Use MenQuadfi in Infants From Six Weeks

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF), Guardant Health (GH) and Pfizer (PFE). Sanofi (SN...

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Guardant Health (GH) and Pfizer (PFE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX) and Sanofi (SNYNF) with bullish se...

Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Sanofi (SNYNF)

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi is running a post-marketing study in Korea to track how its MenQuadfi ...

Sanofi’s MenQuadfi Safety Study in Korea: What Investors Should Watch

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi SA (SNY) has launched a Phase 1/2 study in adults 60+ to test a new co...

Sanofi Targets Dual RSV–HMPV Opportunity With Fresh Phase 1/2 Vaccine Study

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi SA (SNY) has paused a mid stage study testing SAR445399 in adults with...

Sanofi Pauses Key Bronchiectasis Trial, Raising Questions For SNY Investors

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi (SNY) is running a real‑world study called “A Hybrid Cross-sectional a...

Sanofi Advances Real-World Asthma Study, Sharpening Its Long-Term Biologics Strategy

Analysts fell to the sidelines weighing in on Sanofi (SNYNF) and Align Tech (ALGN) with neutral ratings, indicating that the experts are neither bu...

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Align Tech (ALGN)

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi today and set a price target of €95.00. According to TipRanks, Vosser is rank...

J.P. Morgan Remains a Hold on Sanofi (SNYNF)

An announcement from Naturgy Energy Group SA ( ($GASNY) ) is now available. Naturgy Energy Group SA has released its first half 2026 results, outli...

Naturgy Details First-Half 2026 Results and Financial Position

Barclays analyst Peter Crampton maintained a Hold rating on Naturgy Energy Group, S.A. today and set a price target of €30.00. According to TipRank...

Naturgy Energy Group, S.A. (0NPV) Gets a Hold from Barclays

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ramsay Health Care (RMSYF) and Sanofi (SNYNF). Ram...

Analysts Offer Insights on Healthcare Companies: Ramsay Health Care (OtherRMSYF) and Sanofi (OtherSNYNF)

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, officially titled “PRospEctiVe c...

Real-World Asthma Data on Dupixent: What Regeneron and Sanofi Investors Should Know

CLSA analyst maintained a Buy rating on Sany Heavy Equipment International Holdings Co on July 16 and set a price target of HK$12.00. The company’s...

CLSA Sticks to Its Buy Rating for Sany Heavy Equipment International Holdings Co (SNYYF)

UBS analyst maintained a Buy rating on Sany Heavy Equipment International Holdings Co on July 15 and set a price target of HK$9.45. The company’s s...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SNY	$43.72	-0.14%	2.72M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SNY	$43.72	-0.1%	2.72M
3
4
5
6

SNY

Get Sanofi Data in Excel

Get Sanofi Data in Excel